AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Prof Bourquin talks to ecancer at EHA 2012, Amsterdam about studying the processes between leukaemia cells and the surrounding bone marrow using mouse models.
This is carried out by modulating the expression of genes in the stromal layer to establish which genes affect survival of the leukaemia cells.
Prof Bourquin's team use functional genomic screens to carry out a top down approach looking at sub-types of the disease.
The team also use proteomics to establish certain proteins that are uniquely identifiable on the leukaemia cells, giving the potential to improve diagnostics.
Filming supported by Amgen
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Addressing the rise of multiple myeloma in Rwanda
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens